Articles tagged with: Revlimid
A recent retrospective study finds that initial treatment with Revlimid may not prevent myeloma patients from collecting enough stem cells for transplantation.
Many of the study’s results confirm the findings of previous research, which has shown that Revlimid (lenalidomide) reduces a patient’s ability to mobilize stem cells for stem cell collection (see related Beacon news).
However, only 2 percent of the patients in the new study were unable to mobilize enough stem cells for at least a single transplant, and this low overall rate of mobilization failure was the same in …
Stem Cell Remobilization With Mozobil Is Possible – Results of a small retrospective study conducted at City of Hope National Medical Center show that remobilization of stem cells with Mozobil (plerixafor) is possible in multiple myeloma patients. Specifically, the researchers found that most multiple myeloma patients (83 percent) who previously failed to collect enough stem cells with Mozobil to proceed to transplantation collected enough stem cells after a second round of mobilization with Mozobil. For more information, please refer to the study in the journal Transfusion (abstract).
Another Study Finds Link Between Cereblon Levels And Revlimid Efficacy – Results of a retrospective analysis conducted in Austria and Italy show that levels of the protein cereblon in patients’ myeloma cells may impact the efficacy of Revlimid (lenalidomide). The researchers found that newly diagnosed multiple myeloma patients with high cereblon levels responded better to treatment with Revlimid and dexamethasone (Decadron) than those with low cereblon levels. The results of the current study support results of previous studies that showed that cereblon is necessary for the immunomodulatory drugs – particularly Revlimid and Pomalyst (pomalidomide) – to be effective against multiple myeloma (see related Beacon news). For more information, please see the study in the British Journal Of Haematology (abstract).
Stem Cell Transplantation May Be More Effective In Amyloidosis Than Multiple Myeloma – Results of a recent retrospective analysis conducted at the Mayo Clinic indicate that patients with immunoglobulin light-chain amyloidosis may benefit more from stem cell transplantation than patients with multiple myeloma. Specifically, the researchers found that more light chain amyloidosis patients achieved a complete response, compared to multiple myeloma patients (40 percent versus 29 percent, respectively). Overall survival was also superior in patients with amyloidosis (9.4 years versus 5 years, respectively). The researchers found that even among those who achieved a complete response, survival was longer for those with amyloidosis. They therefore hypothesize that the biology of the two diseases is very different, despite the similarity in the two types of plasma cell disorders. For more information, please see the study in the journal Bone Marrow Transplantation (abstract).
Further findings from two clinical studies of Revlimid maintenance therapy were presented at the 14th International Myeloma Workshop (IMW) in Kyoto, Japan, earlier this month.
Both studies involved newly diagnosed multiple myeloma patients who received maintenance therapy with Revlimid (lenalidomide).
Results from both studies, which were published in the New England Journal of Medicine last May, indicate that Revlimid maintenance therapy significantly increases progression-free survival compared to a placebo (see related Beacon news). One of the studies also found that Revlimid maintenance therapy improved overall survival of patients. …
A subgroup analysis of recent Phase 1/2 clinical trial results shows that Kyprolis in combination with Revlimid and low-dose dexamethasone is effective and well tolerated in newly diagnosed multiple myeloma patients over the age of 65.
All of the evaluated patients responded to treatment, with 83 percent of patients reaching at least a near complete response.
According to Dr. Andrzei Jakubowiak of the University of Chicago Medical Center, who presented the findings earlier this month at the International Myeloma Workshop (IMW) in Kyoto, Japan, the response rates compare favorably to …
Velcade-Thalidomide-Dexamethasone Combination May Be Effective After A Stem Cell Transplant In Multiple Myeloma Patients – Results from a French study show that the combination of Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), commonly referred to as VTD, may improve response rates in multiple myeloma patients after stem cell transplantation. The complete response rate for patients who received VTD as a consolidation therapy (52 percent) was significantly higher than the rate for patients who received a placebo (30 percent). The time to progression was also longer in patients who received VTD (62 percent), compared to those who received a placebo (29 percent). All patients had also received VTD as induction therapy prior to stem cell transplantation. For more information, please refer to the letter in the journal Leukemia (abstract).
Revlimid May Not Worsen Pre-Existing Peripheral Neuropathy In Relapsed Or Refractory Myeloma Patients – Results from an Italian study indicate that Revlimid (lenalidomide) does not worsen pre-existing peripheral neuropathy (pain, tingling, and loss of sensation in the extremities due to nerve damage) in relapsed and refractory multiple myeloma patients. The investigators administered Revlimid and dexamethasone to 30 patients who had previously received Velcade or thalidomide. After 12 months of Revlimid therapy, peripheral neuropathy did not worsen in patients with pre-existing peripheral neuropathy and did not develop in any of the patients without pre-existing neuropathy. Based on these results, the investigators recommend longer follow-up studies to confirm Revlimid’s safety in patients with pre-existing peripheral neuropathy. For more information, please see the study in the Journal of the Peripheral Nervous System (abstract).
Heavy/Light Chain Assay May More Effectively Measure M-Protein Levels In Myeloma Patients – Findings from a European study indicate that the heavy/light chain (HLC) assay can be used as an effective prognostic test in patients with multiple myeloma. The investigators found that the HLC assay was better at identifying monoclonal (M) protein levels than other conventional tests, such as serum protein electrophoresis and immunofixation electrophoresis. In addition, the investigators found that the HLC assay was not only more accurate, but could also detect subtle changes in patients with very low M-protein levels. The investigators note that results from the HLC assay and the free light chain (FLC) assay were generally in agreement, but both tests are needed to exclude the presence of residual disease. For more information, please refer to the study in Leukemia (subscription required).